HSBC Holdings’s Iovance Biotherapeutics IOVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$292K Buy
68,190
+40,706
+148% +$155K ﹤0.01% 2530
2026
Q1
$98K Sell
27,484
-153,057
-85% -$490K ﹤0.01% 2753
2025
Q4
$497K Buy
180,541
+156,517
+652% +$362K ﹤0.01% 2318
2025
Q3
$52.3K Sell
24,024
-18,673
-44% -$44.1K ﹤0.01% 2644
2025
Q2
$73.7K Buy
42,697
+26,463
+163% +$65.8K ﹤0.01% 2893
2025
Q1
$53.2K Sell
16,234
-15,711
-49% -$81K ﹤0.01% 2896
2024
Q4
$232K Buy
31,945
+14,045
+78% +$130K ﹤0.01% 2635
2024
Q3
$172K Buy
+17,900
New +$170K ﹤0.01% 2673
2024
Q2
– Sell
-24,644
Closed -$365K – 3056
2024
Q1
$365K Buy
+24,644
New +$287K ﹤0.01% 2290
2022
Q3
– Sell
-10,744
Closed -$118K – 3092
2022
Q2
$118K Buy
+10,744
New +$141K ﹤0.01% 3011
2021
Q4
– Sell
-9,345
Closed -$231K – 3300
2021
Q3
$231K Sell
9,345
-2,138
-19% -$50.4K ﹤0.01% 2699
2021
Q2
$303K Buy
+11,483
New +$298K ﹤0.01% 2507
2021
Q1
– Sell
-5,777
Closed -$271K – 2928
2020
Q4
$271K Sell
5,777
-6,288
-52% -$250K ﹤0.01% 2634
2020
Q3
$400K Buy
12,065
+3,372
+39% +$103K ﹤0.01% 2074
2020
Q2
$239K Buy
+8,693
New +$286K ﹤0.01% 2245

Other funds holding IOVA

HSBC Holdings's IOVA Position: Q2 2026 in Review

HSBC Holdings increased its Iovance Biotherapeutics (IOVA) stake by 148% in Q2 2026, buying an estimated $155K and bringing the position to 68,190 shares worth $292K. The position accounts for ﹤0.01% of the portfolio, ranked #2530.

HSBC Holdings first reported a position in IOVA in Q2 2020 and has held it in 15 quarters since. The position peaked at $497K in Q4 2025. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • HSBC Holdings held 68,190 shares of Iovance Biotherapeutics worth $292K as of Q2 2026.
  • HSBC Holdings bought 40,706 Iovance Biotherapeutics shares in Q2 2026, an estimated $155K.
  • Iovance Biotherapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2530 holding.
  • HSBC Holdings first reported a position in Iovance Biotherapeutics in Q2 2020 and has held it in 15 quarters since.
  • HSBC Holdings's Iovance Biotherapeutics position peaked at $497K in Q4 2025.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.